The treatment of patients with rheumatoid arthritis is challenging, because it is a chronic progressive disease, partially in multi-morbid patients, and various treatment options exist side by side. How to represent the situation of treatment in patients with RA in the Swiss landscape of supply is little researched. The Merck Sharp Dohme company (MSD) is a supplier of drugs in the area of RA. In addition to the distribution of these drugs, the company is engaged in the Switzerland for the promotion of health skills of the people involved and would like to the supply situation of patients examined now with RA in the Switzerland. The aim of this study is the analysis of the strengths and weaknesses of the current supply situation of patients with RA in the Switzerland. The planned study represents a cross-section study with searches in several databases, professional societies, organizations, and interviews with people in the context of clinical care.
